Prakt. lékáren. 2022; 18(3): 183-186

Medical cannabis and its potential use in dermatology

PharmDr. Jaroslav Peč, Ph.D.1, Mgr. Dominika Kaczorová2, Mgr. Tibor Béres, Ph.D.2, doc. RNDr. Petr Tarkowski, Ph.D.2, PharmDr. Jaroslav Matal, Ph.D.3
1 Pharm & Herb, s. r. o., Prostějov
2 Vysokoškolský ústav CATRIN, Univerzita Palackého v Olomouci
3 Oddělení přípravy a kontroly léčiv, desinfekcí a diagnostik, Lékárna Fakultní nemocnice Olomouc

Cannabis for medical use has been successfully incorporated into Czech clinical practice, especially in the fields of algesiology and neurology. Under the current legislation, medical cannabis can also be used in dermatology in the indication surface treatment of dermatoses and mucosal lesions. However, this use is so far neglected, mainly due to the lack of a standardized procedure for the preparation of dermal dosage forms in pharmacies and also due to the unavailability of standardized medicinal cannabis extracts, which are available abroad. However, influencing the endocannabinoid system topically at the skin level provides an interesting pharmacological target for a number of skin diseases. The present review aims to summarize the available information and the potential use of medical cannabis in topical dermal application.

Keywords: cannabis, CBD, THC, dermatology, topical application.

Accepted: October 13, 2022; Published: October 27, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Peč J, Kaczorová D, Béres T, Tarkowski P, Matal J. Medical cannabis and its potential use in dermatology. Praktické lékárenství. 2022;18(3):183-186. doi: 10.36290/lek.2022.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gilca M, Tiplica GS, Salavastru CM. Traditional and ethnobotanical dermatology practices in Romania and other Eastern European countries. Clin Dermatol. 2018 May­‑Jun;36(3):338-352. Go to original source... Go to PubMed...
    2. Proksch E, Soeberdt M, Neumann C, Kilic A, Abels C. Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. Exp Dermatol. 2019 Sep;28(9):1058-1065. Go to original source... Go to PubMed...
    3. Žurnál Univerzity Palackého v Olomouci, 2011;27(20):4-5.
    4. Peč J, Dušek J. Složení a využití konopného oleje se zaměřením na terapeutické účinky esenciálních mastných kyselin. Prakt. Lékáren. 2008;4(2):86-89.
    5. Jeong S, Kim MS, Lee SH, Park BD. Epidermal Endocannabinoid System (EES) and its Cosmetic Application. Cosmetics. 2019;6(2):33. Go to original source...
    6. Karlíčková J. Potenciální léčebné využití kanabidiolu (CBD) z konopí setého. Prakt. Lékáren. 2019;15(4):227-230.
    7. Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System. Molecules. 2019 Mar;24(5):918. Go to original source... Go to PubMed...
    8. Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol. 2009 Aug;18(8):669-79. Go to original source... Go to PubMed...
    9. Scheau C, Badarau IA, Mihai LG, Scheau AE, Costache DO, Constantin C, Calina D, Caruntu C, Costache RS, Caruntu A. Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules. 2020 Feb;25(3):652. Go to original source... Go to PubMed...
    10. Mnekin L, Ripoll L. Topical Use of Cannabis sativa L. Biochemicals. Cosmetics. 2021;8(3):85. Go to original source...
    11. Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018 Nov;157:122-133. Go to original source... Go to PubMed...
    12. Maida V, Shi RB, Fazzari FGT, Zomparelli L. Topical cannabis­‑based medicines - A novel paradigm and treatment for non­‑uremic calciphylaxis leg ulcers: An open label trial. Int Wound J. 2020 Oct;17(5):1508-1516. Go to original source... Go to PubMed...
    13. Jarocka­‑Karpowicz I, Biernacki M, Wroński A, Gęgotek A, Skrzydlewska E. Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris. Biomolecules. 2020 Feb;10(3):367. Go to original source... Go to PubMed...
    14. Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic pruritus: A review. J Am Acad Dermatol. 2020 May;82(5):1205-1212. Go to original source... Go to PubMed...
    15. Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol Sci. 2016 Jul;37(7):594-605. Go to original source... Go to PubMed...
    16. Lowe H, Steele B, Bryant J, Toyang N, Ngwa W. Non­‑Cannabinoid Metabolites of Cannabis sativa L. with Therapeutic Potential. Plants (Basel). 2021;10(2):400. Go to original source... Go to PubMed...
    17. Erridge S, Mangal N, Salazar O, Pacchetti B, Sodergren MH. Cannflavins - From plant to patient: A scoping review. Fitoterapia. 2020 Oct;146:104712. Go to original source... Go to PubMed...
    18. Adler BL, DeLeo VA. Allergenic ingredients in commercial topical cannabinoid preparations. J Am Acad Dermatol. 2019 Sep;81(3):847-848. Go to original source... Go to PubMed...
    19. Biernacki M, Jastrząb A, Skrzydlewska E. Changes in Hepatic Phospholipid Metabolism in Rats under UV Irradiation and Topically Treated with Cannabidiol. Antioxidants (Basel). 2021 Jul;10(8):1157. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.